LOXL2 and malignant colon neoplasm: Additionally, LOXL2 has been mainly researched in individual tumors, including breast cancer [12], hepatocellular carcinoma [13], non-small cell lung cancer [14], cervical cancer [15], colon cancer [16], and esophageal cancer [17], and several studies have found its association with tumor progression, metastasis, chemo-radiotherapy resistance, and worse prognosis [18–21].